enVVeno Medical is entering a critical phase as it advances its , a replacement venous valve for chronic venous insufficiency.
Enovix closed 2025 with $31.8 million in revenue (up 38% YoY) and a robust $621 million cash position . buy envv stock
AI responses may include mistakes. For financial advice, consult a professional. Learn more enVVeno Medical is entering a critical phase as
The stock has recently seen speculative rallies based on rumored partnerships, including a potential battery supply deal with Meta for AR glasses. For financial advice, consult a professional
Wall Street is divided. While the consensus rating is a "Buy" with an average price target of $13.46 , some major firms like Bank of America and Wells Fargo have more cautious targets of $6.00 , citing manufacturing hurdles and long qualification cycles for smartphones. Summary Table: Quick Comparison (April 2026) enVVeno Medical (ENVV) Enovix (ENVX) Primary Focus Medical Devices (Venous Valves) Next-Gen Silicon-Anode Batteries Recent Price ~$5.10 (as of 4/27/26) ~$6.51 (as of 4/27/26) Outlook High-risk trial phase Scaling manufacturing in Malaysia Catalysts enVVe pivotal trial start Q1 Earnings on May 13, 2026
Are you more interested in the of enVVeno or the hardware scalability of Enovix for your portfolio?